Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis

• Published in: Science translational medicine Vol. 11; no. 515
• Main Authors: Chen, Yi-Ling, Gutowska-Owsiak, Danuta, Hardman, Clare S, Westmoreland, Melanie, MacKenzie, Teena, Cifuentes, Liliana, Waithe, Dominic, Lloyd-Lavery, Antonia, Marquette, Allison, Londei, Marco, Ogg, Graham
• Format: Journal Article
• Language: English
• Published: United States 23.10.2019
• Subjects: Antibodies, Monoclonal - immunology; Antibodies, Monoclonal - therapeutic use; Cell Movement - drug effects; Dermatitis, Atopic - drug therapy; Dermatitis, Atopic - immunology; Dermatitis, Atopic - metabolism; Eczema - immunology; Eczema - metabolism; Extracellular Fluid; Humans; Inflammation - drug therapy; Inflammation - immunology; Inflammation - metabolism; Interleukin-12 - metabolism; Interleukin-33 - immunology; Interleukin-33 - metabolism; Neutrophils - drug effects; Neutrophils - metabolism; Receptors, Interleukin-8A - metabolism; Skin - drug effects; Skin - immunology; Skin - metabolism

Targeted inhibition of cytokine pathways provides opportunities to understand fundamental biology in vivo in humans. The IL-33 pathway has been implicated in the pathogenesis of atopy through genetic and functional associations. We investigated the role of IL-33 inhibition in a first-in-class phase...